HIV Integrase Inhibitors [MoA]: Side Effects & Safety Data for 3 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
HIV Integrase Inhibitors [MoA] includes 3 drugs with a combined 27,688 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
3
Drugs in Class
27,688
Combined Reports
All HIV Integrase Inhibitors [MoA] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| DOLUTEGRAVIR | Juluca | 10,772 | 1,001 | 2,225 | 9.3% |
| RALTEGRAVIR | ISENTRESS | 8,612 | 985 | 2,088 | 11.4% |
| CABOTEGRAVIR | Apretude | 8,304 | 144 | 428 | 1.7% |
Common Side Effects in HIV Integrase Inhibitors [MoA] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Foetal exposure during pregnancy | 2,099 | 236 |
| Off label use | 1,650 | 179 |
| Exposure during pregnancy | 1,632 | 133 |
| Virologic failure | 1,562 | 29 |
| Product dose omission issue | 1,475 | 1 |
| Pathogen resistance | 1,281 | 4 |
| Maternal exposure during pregnancy | 1,251 | 35 |
| Viral mutation identified | 963 | 6 |
| Injection site pain | 924 | 3 |
| Death | 887 | 881 |